

Arthur Kavanaugh

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/929593/publications.pdf>

Version: 2024-02-01

231
papers

18,390
citations

26630

56
h-index

13379

130
g-index

235
all docs

235
docs citations

235
times ranked

12714
citing authors

#	ARTICLE	IF	CITATIONS
1	2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis and Rheumatology, 2016, 68, 1-26.	5.6	1,880
2	Rheumatoid arthritis. Nature Reviews Disease Primers, 2018, 4, 18001.	30.5	1,441
3	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. Arthritis and Rheumatology, 2016, 68, 1060-1071.	5.6	726
4	Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, The, 2015, 386, 1137-1146.	13.7	722
5	Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet, The, 2013, 382, 780-789.	13.7	688
6	Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis. New England Journal of Medicine, 2015, 373, 1329-1339.	27.0	629
7	Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis and Rheumatism, 2005, 52, 1227-1236.	6.7	583
8	Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Annals of the Rheumatic Diseases, 2014, 73, 990-999.	0.9	576
9	Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis and Rheumatism, 2009, 60, 976-986.	6.7	547
10	Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet, The, 2009, 373, 633-640.	13.7	545
11	Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. Journal of the American Academy of Dermatology, 2019, 80, 1029-1072.	1.2	542
12	Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Annals of the Rheumatic Diseases, 2018, 77, 3-17.	0.9	484
13	Patient perspectives in the management of psoriasis: Results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. Journal of the American Academy of Dermatology, 2014, 70, 871-881.e30.	1.2	423
14	Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Annals of the Rheumatic Diseases, 2014, 73, 6-16.	0.9	397
15	Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Annals of the Rheumatic Diseases, 2014, 73, 1020-1026.	0.9	372
16	Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis. Annals of the Rheumatic Diseases, 2010, 69, 1441-1447.	0.9	274
17	Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. Annals of the Rheumatic Diseases, 2014, 73, 1000-1006.	0.9	255
18	Treat to Target: A Proposed New Paradigm for the Management of Crohn's Disease. Clinical Gastroenterology and Hepatology, 2015, 13, 1042-1050.e2.	4.4	240

#	ARTICLE	IF	CITATIONS
19	Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: the randomised controlled OPTIMA trial. <i>Lancet, The</i> , 2014, 383, 321-332.	13.7	232
20	Interleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis. <i>Immunology</i> , 2014, 141, 133-142.	4.4	200
21	Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 64-71.	0.9	183
22	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. <i>Nature Reviews Rheumatology</i> , 2022, 18, 465-479.	8.0	182
23	Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial. <i>Lancet, The</i> , 2020, 395, 1496-1505.	13.7	178
24	US Perspectives in the Management of Psoriasis and Psoriatic Arthritis: Patient and Physician Results from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey. <i>American Journal of Clinical Dermatology</i> , 2016, 17, 87-97.	6.7	173
25	Golimumab in psoriatic arthritis: One-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , 2012, 64, 2504-2517.	6.7	171
26	Psoriatic Arthritis and Burden of Disease: Patient Perspectives from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey. <i>Rheumatology and Therapy</i> , 2016, 3, 91-102.	2.3	146
27	Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2). <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1984-1988.	0.9	131
28	Longterm (52-week) Results of a Phase III Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2015, 42, 479-488.	2.0	122
29	Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial. <i>Lancet, The</i> , 2020, 395, 427-440.	13.7	122
30	Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis. <i>American Journal of Medicine</i> , 2002, 113, 400-408.	1.5	114
31	Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012: Table A1. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, ii2-ii34.	0.9	114
32	Psoriatic arthritis. <i>Nature Reviews Disease Primers</i> , 2021, 7, 59.	30.5	113
33	Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study). <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1689-1694.	0.9	112
34	The modified Nail Psoriasis Severity Index: validation of an instrument to assess psoriatic nail involvement in patients with psoriatic arthritis. <i>Journal of Rheumatology</i> , 2007, 34, 123-9.	2.0	105
35	Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). <i>Journal of Rheumatology</i> , 2008, 35, 869-76.	2.0	102
36	Alterations in immune function with biologic therapies for autoimmune disease. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 19-27.	2.9	101

#	ARTICLE	IF	CITATIONS
37	Infantile Hemangiomas: An Updated Review on Risk Factors, Pathogenesis, and Treatment. Birth Defects Research, 2017, 109, 809-815.	1.5	101
38	Influence of Axial Involvement on Clinical Characteristics of Psoriatic Arthritis: Analysis from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. Journal of Rheumatology, 2018, 45, 1389-1396.	2.0	100
39	A Comparison of Disease Burden in Rheumatoid Arthritis, Psoriatic Arthritis and Axial Spondyloarthritis. PLoS ONE, 2015, 10, e0123582.	2.5	94
40	Clinical Characteristics, Disease Activity, and Patient-Reported Outcomes in Psoriatic Arthritis Patients With Dactylitis or Enthesitis: Results From the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. Arthritis Care and Research, 2017, 69, 1692-1699.	3.4	91
41	Safety and Efficacy of Intravenous Golimumab in Patients With Active Psoriatic Arthritis. Arthritis and Rheumatology, 2017, 69, 2151-2161.	5.6	90
42	Postapproval Comparative Safety Study of Tofacitinib and Biological Disease-Modifying Antirheumatic Drugs: 5-Year Results from a United States-Based Rheumatoid Arthritis Registry. ACR Open Rheumatology, 2021, 3, 173-184.	2.1	88
43	Maintenance of Clinical Efficacy and Radiographic Benefit Through Two Years of Ustekinumab Therapy in Patients With Active Psoriatic Arthritis: Results From a Randomized, Placebo-Controlled Phase III Trial. Arthritis Care and Research, 2015, 67, 1739-1749.	3.4	87
44	Effect of certolizumab pegol with methotrexate on home and work place productivity and social activities in patients with active rheumatoid arthritis. Arthritis and Rheumatism, 2009, 61, 1592-1600.	6.7	78
45	Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trial. Arthritis Research and Therapy, 2009, 11, R170.	3.5	78
46	Clinical efficacy, radiographic and safety findings through 2...years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study. Annals of the Rheumatic Diseases, 2013, 72, 1777-1785.	0.9	77
47	Efficacy of Subcutaneous Secukinumab in Patients with Active Psoriatic Arthritis Stratified by Prior Tumor Necrosis Factor Inhibitor Use: Results from the Randomized Placebo-controlled FUTURE 2 Study. Journal of Rheumatology, 2016, 43, 1713-1717.	2.0	77
48	Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. Annals of the Rheumatic Diseases, 2015, 74, 538-546.	0.9	75
49	International spondyloarthritis interobserver reliability exercise--the INSPIRE study: II. Assessment of peripheral joints, enthesitis, and dactylitis. Journal of Rheumatology, 2007, 34, 1740-5.	2.0	74
50	Qualifying Unmet Needs and Improving Standards of Care in Psoriatic Arthritis. Arthritis Care and Research, 2014, 66, 1759-1766.	3.4	73
51	Secukinumab for Long-Term Treatment of Psoriatic Arthritis: A Two-Year Followup From a Phase III, Randomized, Double-Blind Placebo-Controlled Study. Arthritis Care and Research, 2017, 69, 347-355.	3.4	72
52	Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations. Nature Reviews Rheumatology, 2016, 12, 743-750.	8.0	71
53	Benefits and risks of low-dose glucocorticoid treatment in the patient with rheumatoid arthritis. Rheumatology, 2014, 53, 1742-1751.	1.9	69
54	Radiographic Progression of Patients With Psoriatic Arthritis Who Achieve Minimal Disease Activity in Response to Golimumab Therapy: Results Through 5 Years of a Randomized, Placebo-Controlled Study. Arthritis Care and Research, 2016, 68, 267-274.	3.4	69

#	ARTICLE	IF	CITATIONS
55	On the HUNT for cardiovascular risk factors and disease in patients with psoriatic arthritis: population-based data from the Nord-Trøndelag Health Study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 819-824.	0.9	61
56	A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of 2 Dosing Regimens of Fostamatinib in Patients with Rheumatoid Arthritis with an Inadequate Response to a Tumor Necrosis Factor- α Antagonist. <i>Journal of Rheumatology</i> , 2014, 41, 2120-2128.	2.0	57
57	Comparison of Composite Measures of Disease Activity in Psoriatic Arthritis Using Data From an Interventional Study With Golimumab. <i>Arthritis Care and Research</i> , 2014, 66, 749-756.	3.4	56
58	Psoriatic arthritis: current therapy and future approaches. <i>Rheumatology</i> , 2015, 54, 20-28.	1.9	56
59	Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial. <i>RMD Open</i> , 2018, 4, e000723.	3.8	56
60	Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1-3 pooled analysis. <i>Arthritis Research and Therapy</i> , 2019, 21, 118.	3.5	55
61	Adverse reactions to biologic agents: Focus on autoimmune disease therapies. <i>Journal of Allergy and Clinical Immunology</i> , 2005, 116, 900-905.	2.9	54
62	Outcome measures in psoriatic arthritis. <i>Current Rheumatology Reports</i> , 2005, 7, 195-200.	4.7	51
63	Tumor necrosis factor as a therapeutic target of rheumatologic disease. <i>Expert Opinion on Therapeutic Targets</i> , 2007, 11, 1369-1384.	3.4	51
64	Effect of ustekinumab on physical function and health-related quality of life in patients with psoriatic arthritis: a randomized, placebo-controlled, phase II trial. <i>Current Medical Research and Opinion</i> , 2010, 26, 2385-2392.	1.9	51
65	Markers of inflammation and bone remodelling associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumab. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 83-88.	0.9	51
66	Pro- and anti-inflammatory eicosanoids in psoriatic arthritis. <i>Metabolomics</i> , 2019, 15, 65.	3.0	49
67	Psoriatic arthritis: latest treatments and their place in therapy. <i>Therapeutic Advances in Chronic Disease</i> , 2015, 6, 194-203.	2.5	48
68	Patient-Reported Outcomes and the Association With Clinical Response in Patients With Active Psoriatic Arthritis Treated With Golimumab: Findings Through 2 Years of a Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Trial. <i>Arthritis Care and Research</i> , 2013, 65, 1666-1673.	3.4	44
69	Economic consequences of established rheumatoid arthritis and its treatment. <i>Best Practice and Research in Clinical Rheumatology</i> , 2007, 21, 929-942.	3.3	43
70	Functional status and radiographic joint damage are associated with health economic outcomes in patients with rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2004, 31, 849-55.	2.0	42
71	Ultrasonographic evaluation in psoriatic arthritis is of major importance in evaluating disease activity. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 2108-2113.	0.9	40
72	The impact of infliximab treatment on quality of life in patients with inflammatory rheumatic diseases. <i>Arthritis Research and Therapy</i> , 2007, 9, R103.	3.5	39

#	ARTICLE	IF	CITATIONS
73	Patient-reported outcomes in rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2012, 24, 327-334.	4.3	39
74	Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Psoriatic Arthritis: Final 5-year Results from the Phase 3 FUTURE 1 Study. <i>ACR Open Rheumatology</i> , 2020, 2, 18-25.	2.1	39
75	Effect of infliximab therapy on employment, time lost from work, and productivity in patients with psoriatic arthritis. <i>Journal of Rheumatology</i> , 2006, 33, 2254-9.	2.0	39
76	Treatment of Psoriatic Arthritis with Tumor Necrosis Factor Inhibitors: Longer-term Outcomes Including Enthesitis and Dactylitis with Golimumab Treatment in the Longterm Extension of a Randomized, Placebo-controlled Study (GO-REVEAL). <i>Journal of rheumatology Supplement</i> , The, 2012, 89, 90-93.	2.2	38
77	Systematic Review of Treatments for Psoriatic Arthritis: 2014 Update for the GRAPPA. <i>Journal of Rheumatology</i> , 2014, 41, 2273-2276.	2.0	37
78	Bedside to bench: defining the immunopathogenesis of psoriatic arthritis. <i>Nature Reviews Rheumatology</i> , 2019, 15, 645-656.	8.0	37
79	Radiographic Progression According to Baseline C-reactive Protein Levels and Other Risk Factors in Psoriatic Arthritis Treated with Tofacitinib or Adalimumab. <i>Journal of Rheumatology</i> , 2019, 46, 1089-1096.	2.0	37
80	The evolving use of tumor necrosis factor inhibitors in rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2004, 31, 1881-4.	2.0	37
81	Rheumatoid arthritis in dermatology. <i>Clinics in Dermatology</i> , 2006, 24, 430-437.	1.6	36
82	Comparison of employability outcomes among patients with early or long-standing rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2008, 59, 510-514.	6.7	36
83	New GRAPPA and EULAR recommendations for the management of psoriatic arthritis. <i>Rheumatology</i> , 2017, 56, kew390.	1.9	36
84	Serum metabolomic profiling predicts synovial gene expression in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2018, 20, 164.	3.5	36
85	Update on anti-tumor necrosis factor therapy in the spondyloarthropathies including psoriatic arthritis. <i>Current Opinion in Rheumatology</i> , 2006, 18, 347-353.	4.3	35
86	Anakinra (Interleukin-1 Receptor Antagonist) has positive effects on function and quality of life in patients with rheumatoid arthritis. <i>Advances in Therapy</i> , 2006, 23, 208-217.	2.9	34
87	Comprehensive disease control (CDC): what does achieving CDC mean for patients with rheumatoid arthritis?. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 2165-2174.	0.9	33
88	Three-dimensional ultrashort echo time cones (3D UTE-Cones) magnetic resonance imaging of entheses and tendons. <i>Magnetic Resonance Imaging</i> , 2018, 49, 4-9.	1.8	33
89	Achilles enthesitis defined by ultrasound is not associated with clinical enthesitis in patients with psoriatic arthritis. <i>RMD Open</i> , 2017, 3, e000486.	3.8	32
90	Economic Burden of Psoriatic Arthritis. <i>Pharmacoeconomics</i> , 2008, 26, 121-129.	3.3	31

#	ARTICLE	IF	CITATIONS
91	Predicting low disease activity and remission using early treatment response to antitumour necrosis factor therapy in patients with rheumatoid arthritis: exploratory analyses from the TEMPO trial. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 206-212.	0.9	31
92	Metabolomic profiling predicts outcome of rituximab therapy in rheumatoid arthritis. <i>RMD Open</i> , 2016, 2, e000289.	3.8	31
93	Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1&2 studies. <i>RMD Open</i> , 2018, 4, e000669.	3.8	31
94	Predictors of Achieving Remission among Patients with Psoriatic Arthritis Initiating a Tumor Necrosis Factor Inhibitor. <i>Journal of Rheumatology</i> , 2019, 46, 475-482.	2.0	31
95	Psoriatic arthritis: exploring the occurrence of sleep disturbances, fatigue, and depression and their correlates. <i>Arthritis Research and Therapy</i> , 2020, 22, 198.	3.5	31
96	Value of the Routine Assessment of Patient Index Data 3 in Patients With Psoriatic Arthritis: Results From a Tight&Control Clinical Trial and an Observational Cohort. <i>Arthritis Care and Research</i> , 2018, 70, 1198-1205.	3.4	29
97	The contribution of joint and skin improvements to the health-related quality of life of patients with psoriatic arthritis: a post hoc analysis of two randomised controlled studies. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1215-1219.	0.9	29
98	Assessing structural damage progression in psoriatic arthritis and its role as an outcome in research. <i>Arthritis Research and Therapy</i> , 2020, 22, 18.	3.5	29
99	Safety and Efficacy of Filgotinib: Up to 4-year Results From an Open-label Extension Study of Phase II Rheumatoid Arthritis Programs. <i>Journal of Rheumatology</i> , 2021, 48, 1230-1238.	2.0	29
100	The effect of golimumab on haemoglobin levels in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. <i>Rheumatology</i> , 2013, 52, 1845-1855.	1.9	28
101	Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind EQUIRA study. <i>RMD Open</i> , 2018, 4, e000757.	3.8	28
102	Patient-derived Joint Counts Are a Potential Alternative for Determining Disease Activity Score. <i>Journal of Rheumatology</i> , 2010, 37, 1035-1041.	2.0	25
103	Treatments for Nail Psoriasis: A Systematic Review by the GRAPPA Nail Psoriasis Work Group. <i>Journal of Rheumatology</i> , 2014, 41, 2306-2314.	2.0	25
104	Frequency, distribution and immunologic nature of infusion reactions in subjects receiving pegloticase for chronic refractory gout. <i>Arthritis Research and Therapy</i> , 2017, 19, 191.	3.5	25
105	Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial. <i>RMD Open</i> , 2017, 3, e000415.	3.8	24
106	Information technology in rheumatology. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 1.	0.8	24
107	Predictors of disease activity and structural progression after treatment with adalimumab plus methotrexate or continued methotrexate monotherapy in patients with early rheumatoid arthritis and suboptimal response to methotrexate. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1566-1572.	0.9	23
108	Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients. <i>Arthritis Research and Therapy</i> , 2015, 17, 245.	3.5	22

#	ARTICLE	IF	CITATIONS
109	Testing treat-to-target outcomes with initial methotrexate monotherapy compared with initial tumour necrosis factor inhibitor (adalimumab) plus methotrexate in early rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 289-292.	0.9	22
110	Allele and antigen-specific treatment of rheumatoid arthritis: a double blind, placebo controlled phase 1 trial. <i>Journal of Rheumatology</i> , 2003, 30, 449-54.	2.0	22
111	Impact of skin, musculoskeletal and psychosocial aspects on quality of life in psoriatic arthritis patients: A cross-sectional study of outpatient clinic patients in the biologic treatment era. <i>RMD Open</i> , 2020, 6, e001223.	3.8	21
112	Filgotinib, a novel JAK1-preferential inhibitor for the treatment of rheumatoid arthritis: An overview from clinical trials. <i>Modern Rheumatology</i> , 2022, 32, 1-11.	1.8	21
113	Adult Inflammatory Arthritides: What the Radiologist Should Know. <i>Radiographics</i> , 2016, 36, 1849-1870.	3.3	20
114	Clinical and Patient-reported Outcomes in Patients with Psoriatic Arthritis (PsA) by Body Surface Area Affected by Psoriasis: Results from the Corrona PsA/Spondyloarthritis Registry. <i>Journal of Rheumatology</i> , 2017, 44, 1151-1158.	2.0	20
115	Osteoporosis in psoriatic arthritis: a cross-sectional study of an outpatient clinic population. <i>RMD Open</i> , 2018, 4, e000631.	3.8	20
116	Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study. <i>Arthritis Research and Therapy</i> , 2019, 21, 130.	3.5	19
117	Adiposity and Physical Activity as Risk Factors for Developing Psoriatic Arthritis: Longitudinal Data From a Population-Based Study in Norway. <i>Arthritis Care and Research</i> , 2021, 73, 432-441.	3.4	19
118	Need for Improvement in Current Treatment of Psoriatic Arthritis: Study of an Outpatient Clinic Population. <i>Journal of Rheumatology</i> , 2017, 44, 431-436.	2.0	18
119	CNS Lymphocytic Vasculitis in a Young Woman With COVID-19 Infection. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	6.0	18
120	Economic issues with new rheumatologic therapeutics. <i>Current Opinion in Rheumatology</i> , 2007, 19, 272-276.	4.3	17
121	Effect of high-intensity interval training on cardiovascular disease risk factors and body composition in psoriatic arthritis: a randomised controlled trial. <i>RMD Open</i> , 2018, 4, e000729.	3.8	17
122	Efficacy of ustekinumab in biologic-naïve patients with psoriatic arthritis by prior treatment exposure and disease duration: data from PSUMMIT 1 and PSUMMIT 2. <i>RMD Open</i> , 2019, 5, e000990.	3.8	17
123	Inhibition of IL6 in rheumatoid arthritis and juvenile idiopathic arthritis. <i>Experimental Cell Research</i> , 2011, 317, 1286-1292.	2.6	16
124	A review of disease activity measures for psoriatic arthritis: what is the best approach?. <i>Expert Review of Clinical Immunology</i> , 2014, 10, 1241-1254.	3.0	16
125	Impact of tocilizumab monotherapy on patient-reported outcomes in patients with rheumatoid arthritis from two randomised controlled trials. <i>RMD Open</i> , 2017, 3, e000496.	3.8	16
126	Ten years of follow-up data in psoriatic arthritis: results based on standardized monitoring of patients in an ordinary outpatient clinic in southern Norway. <i>Arthritis Research and Therapy</i> , 2018, 20, 160.	3.5	16

#	ARTICLE	IF	CITATIONS
127	Effect of adalimumab on the work-related outcomes scores in patients with early rheumatoid arthritis receiving methotrexate. <i>Rheumatology</i> , 2016, 55, 1458-1465.	1.9	15
128	Benefit of biologics initiation in moderate versus severe rheumatoid arthritis: evidence from a United States registry. <i>Rheumatology</i> , 2017, 56, 1095-1101.	1.9	15
129	Incidence and Predictors of Biological Antirheumatic Drug Discontinuation Attempts among Patients with Rheumatoid Arthritis in Remission: A CORRONA and Ninja Collaborative Cohort Study. <i>Journal of Rheumatology</i> , 2015, 42, 2238-2246.	2.0	14
130	Advances in use of immunomodulatory agents—a rheumatology perspective. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2015, 12, 363-368.	17.8	14
131	Clinical Remission in Patients with Active Psoriatic Arthritis Treated with Adalimumab and Correlations in Joint and Skin Manifestations. <i>Journal of Rheumatology</i> , 2015, 42, 952-959.	2.0	14
132	Efficacy and Safety of Intravenous Golimumab Through One Year in Patients With Active Psoriatic Arthritis. <i>Arthritis Care and Research</i> , 2020, 72, 806-813.	3.4	14
133	GRAPPA Treatment Recommendations: An Update From the 2020 GRAPPA Annual Meeting. <i>Journal of Rheumatology</i> , 2021, , jrheum.201681.	2.0	14
134	Choline metabolite, trimethylamine N-oxide (TMAO), is associated with inflammation in psoriatic arthritis. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 481-484.	0.8	14
135	Radiographic Progression in Psoriatic Arthritis Achieving a Good Response to Treatment: Data Using Newer Composite Indices of Disease Activity. <i>Arthritis Care and Research</i> , 2018, 70, 797-800.	3.4	13
136	Long-term Safety and Tolerability of Apremilast Versus Placebo in Psoriatic Arthritis: A Pooled Safety Analysis of Three Phase III, Randomized, Controlled Trials. <i>ACR Open Rheumatology</i> , 2020, 2, 459-470.	2.1	12
137	Differences in oxylipin profile in psoriasis versus psoriatic arthritis. <i>Arthritis Research and Therapy</i> , 2021, 23, 200.	3.5	12
138	GRAPPA Treatment Recommendations: Updates and Methods. <i>Journal of Rheumatology</i> , 2020, 96, 41-45.	2.0	12
139	GRAPPA Treatment Recommendations: 2021 Update. <i>Journal of Rheumatology</i> , 2022, , jrheum.211331.	2.0	12
140	Potential Impact of Sex and BMI on Response to Therapy in Psoriatic Arthritis: Post Hoc Analysis of Results From the SEAM-PsA Trial. <i>Journal of Rheumatology</i> , 2022, 49, 885-893.	2.0	12
141	Development and initial evaluation of a culturally sensitive cholesterol-lowering diet program for Mexican and African American patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2000, 13, 205-212.	6.7	11
142	Combination cytokine therapy: The next generation of rheumatoid arthritis therapy?. <i>Arthritis and Rheumatism</i> , 2002, 47, 87-92.	6.7	11
143	Secondary immune deficiencies associated with biological therapeutics. <i>Current Allergy and Asthma Reports</i> , 2003, 3, 389-395.	5.3	11
144	Infection prophylaxis in antirheumatic therapy: emphasis on vaccination. <i>Current Opinion in Rheumatology</i> , 2009, 21, 419-424.	4.3	11

#	ARTICLE	IF	CITATIONS
145	Treatment of Psoriatic Arthritis with Biological Agents. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2010, 29, 56-62.	1.6	11
146	Can we improve the performance and reporting of investigator-initiated clinical trials? Rheumatoid arthritis as an example: Table A1. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1755-1760.	0.9	11
147	Psoriatic Arthritis: Newer and Older Therapies. <i>Current Rheumatology Reports</i> , 2019, 21, 75.	4.7	11
148	Final 10-year effectiveness and safety results from study DE020: adalimumab treatment in patients with rheumatoid arthritis and an inadequate response to standard therapy. <i>Rheumatology</i> , 2015, 54, kev249.	1.9	10
149	Demography, baseline disease characteristics, and treatment history of psoriasis patients with self-reported psoriatic arthritis enrolled in the PSOLAR registry. <i>BMC Rheumatology</i> , 2018, 2, 29.	1.6	10
150	An overview of low disease activity and remission in psoriatic arthritis. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S51-4.	0.8	10
151	Adalimumab for the treatment of rheumatoid arthritis. <i>Therapy: Open Access in Clinical Medicine</i> , 2005, 2, 13-21.	0.2	9
152	Novel therapies for rheumatoid arthritis. <i>Pathophysiology</i> , 2005, 12, 217-225.	2.2	9
153	The Pharmacoeconomics of Newer Therapeutics for Rheumatic Diseases. <i>Rheumatic Disease Clinics of North America</i> , 2006, 32, 45-56.	1.9	9
154	The efficacy of ustekinumab on the articular and dermatologic manifestations of psoriatic arthritis. <i>Current Rheumatology Reports</i> , 2009, 11, 233-234.	4.7	9
155	Psoriatic arthritis: current therapy and future directions. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 1755-1764.	1.8	9
156	Bone mineral density in patients with psoriatic arthritis: data from the Nord-Trøndelag Health Study 3. <i>RMD Open</i> , 2017, 3, e000413.	3.8	9
157	Long-Term Radiographic and Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Treated with Tofacitinib: ORAL Start and ORAL Scan Post-hoc Analyses. <i>Rheumatology and Therapy</i> , 2018, 5, 341-353.	2.3	9
158	Baseline patient characteristics associated with response to biologic therapy in patients with psoriatic arthritis enrolled in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. <i>RMD Open</i> , 2018, 4, e000638.	3.8	9
159	Imbalance Between Omega-6- and Omega-3-Derived Bioactive Lipids in Arthritis in Older Adults. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2021, 76, 415-425.	3.6	9
160	Reading and interpreting economic evaluations in rheumatoid arthritis: an assessment of selected instruments for critical appraisal. <i>Journal of Rheumatology</i> , 2003, 30, 1739-47.	2.0	9
161	Biologic Agents in Rheumatology: Safety Considerations. <i>Rheumatic Disease Clinics of North America</i> , 2006, 32, 3-10.	1.9	8
162	Desirability Scores for Assessing Multiple Outcomes in Systemic Rheumatic Diseases. <i>Communications in Statistics - Theory and Methods</i> , 2009, 38, 3461-3471.	1.0	8

#	ARTICLE	IF	CITATIONS
163	Change in cardiovascular risk factors in patients who develop psoriatic arthritis: longitudinal data from the Nord-Trøndelag Health Study (HUNT). RMD Open, 2018, 4, e000630.	3.8	8
164	Treat to Target in Psoriatic Arthritis. Rheumatic Disease Clinics of North America, 2019, 45, 505-517.	1.9	8
165	Interleukin-6 inhibition and clinical efficacy in rheumatoid arthritis treatment—data from randomized clinical trials. Bulletin of the NYU Hospital for Joint Diseases, 2007, 65 Suppl 1, S16-20.	0.7	8
166	Salivary Gland Ultrasonography as a Diagnostic Tool for Secondary Sjögren Syndrome in Rheumatoid Arthritis. Journal of Rheumatology, 2015, 42, 1119-1122.	2.0	7
167	Certolizumab pegol for the treatment of psoriatic arthritis. Expert Review of Clinical Immunology, 2015, 11, 307-318.	3.0	7
168	Secukinumab for the treatment of psoriatic arthritis. Expert Review of Clinical Immunology, 2016, 12, 1027-1036.	3.0	7
169	The role of golimumab in inflammatory arthritis. A review of the evidence. Therapeutic Advances in Musculoskeletal Disease, 2018, 10, 181-194.	2.7	7
170	GRAPPA 2018 Project Report. Journal of Rheumatology, 2019, 95, 54-57.	2.0	7
171	Secukinumab in United States Biologic-Naïve Patients With Psoriatic Arthritis: Results From the Randomized, Placebo-Controlled CHOICE Study. Journal of Rheumatology, 2022, 49, 894-902.	2.0	7
172	Novel Treatment Concepts in Psoriatic Arthritis. Rheumatic Disease Clinics of North America, 2015, 41, 739-754.	1.9	6
173	Risk of infantile hemangiomas in the offspring of women with autoimmune disease and the pathogenic implications of these lesions. American Journal of Medical Genetics, Part A, 2018, 176, 570-577.	1.2	6
174	Radiographic Progression Inhibition with Intravenous Golimumab in Psoriatic Arthritis: Week 24 Results of a Phase III, Randomized, Double-blind, Placebo-controlled Trial. Journal of Rheumatology, 2019, 46, 595-602.	2.0	6
175	OP0108—DUAL NEUTRALISATION OF IL-17A AND IL-17F WITH BIMEKIZUMAB IN PATIENTS WITH ACTIVE PSA: OVERALL AND TNF-INHIBITOR-NAÏVE POPULATION RESULTS FROM A 48-WEEK PHASE 2B RANDOMISED STUDY. , 2019, , .		6
176	Psoriatic arthritis: treat-to-target. Clinical and Experimental Rheumatology, 2012, 30, S123-5.	0.8	6
177	Ixekizumab improves patient-reported outcomes in patients with active psoriatic arthritis and inadequate response to tumour necrosis factor inhibitors: SPIRIT-P2 results to 52 weeks. Clinical and Experimental Rheumatology, 2019, 37, 566-574.	0.8	6
178	Early Real-World Experience of Tofacitinib for Psoriatic Arthritis: Data from a United States Healthcare Claims Database. Advances in Therapy, 2022, 39, 2932-2945.	2.9	6
179	Sex difference in disease burden of inflammatory arthritis patients treated with tumor necrosis factor inhibitors as part of standard care. PLoS ONE, 2022, 17, e0266816.	2.5	6
180	Novel approaches to biological therapy for psoriatic arthritis. Expert Opinion on Biological Therapy, 2016, 16, 173-186.	3.1	5

#	ARTICLE	IF	CITATIONS
181	Achieving comprehensive disease control in patients with early and established rheumatoid arthritis treated with adalimumab plus methotrexate versus methotrexate alone. RMD Open, 2017, 3, e000445.	3.8	5
182	Golimumab in the treatment of psoriatic arthritis. Expert Review of Clinical Immunology, 2018, 14, 893-898.	3.0	5
183	Disease activity and biologic use in patients with psoriatic arthritis or rheumatoid arthritis. Clinical Rheumatology, 2018, 37, 2275-2280.	2.2	5
184	Exposure-Response Relationship of Certolizumab Pegol and Achievement of Low Disease Activity and Remission in Patients With Rheumatoid Arthritis. Clinical and Translational Science, 2020, 13, 743-751.	3.1	5
185	Interleukin-17 inhibition in psoriatic arthritis. Clinical and Experimental Rheumatology, 2015, 33, S119-23.	0.8	5
186	Guidelines for RA therapy-avoiding hamartia. Nature Reviews Rheumatology, 2010, 6, 505-506.	8.0	4
187	Pregnancy: Data, Outcomes, and Treatment Paradigms in Rheumatology. Journal of Rheumatology, 2015, 42, 1357-1358.	2.0	4
188	International Treatment Recommendations Update: A Report from the GRAPPA 2016 Annual Meeting. Journal of Rheumatology, 2017, 44, 684-685.	2.0	4
189	Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Arthritis Research and Therapy, 2022, 24, 73.	3.5	4
190	Baseline Disease Activity Predicts Achievement of cDAPSA Treatment Targets With Apremilast: Phase III Results in DMARD-naïve Patients With Psoriatic Arthritis. Journal of Rheumatology, 2022, 49, 694-699.	2.0	4
191	Biomarkers in rheumatology: promise and pitfalls. Future Rheumatology, 2008, 3, 303-305.	0.2	3
192	Anti-cytokine Therapies. , 2017, , 999-1019.		3
193	FRI0451-SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS IN PSORIATIC ARTHRITIS: FINAL 5 YEAR EFFICACY AND SAFETY RESULTS FROM A PHASE 3 TRIAL. , 2019, , .		3
194	Effects of Intravenous Golimumab on Health-Related Quality of Life in Patients With Psoriatic Arthritis: 24-Week Results of the GO-VIBRANT Trial. Value in Health, 2020, 23, 1286-1291.	0.3	3
195	Inhibition of radiographic progression across levels of composite index-defined disease activity in patients with active psoriatic arthritis treated with intravenous golimumab: results from a phase-3, double-blind, placebo-controlled trial. Arthritis Research and Therapy, 2020, 22, 43.	3.5	3
196	The effect of intravenous golimumab on health-related quality of life and work productivity in patients with active psoriatic arthritis: results of the Phase 3 GO-VIBRANT trial. Clinical Rheumatology, 2021, 40, 3667-3677.	2.2	3
197	Lipidomic Profiling in Synovial Tissue. Frontiers in Medicine, 2022, 9, 857135.	2.6	3
198	Correspondence on "No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related" physician-reported spondylitis. Annals of the Rheumatic Diseases, 2023, 82, e187-e187.	0.9	3

#	ARTICLE	IF	CITATIONS
199	Is there a pharmacoeconomic argument supporting the use of tumor necrosis factor inhibitors in early rheumatoid arthritis?. <i>Nature Clinical Practice Rheumatology</i> , 2006, 2, 346-347.	3.2	2
200	Oral Abstracts 7: RA Clinical * O37. Long-Term Outcomes of Early RA Patients Initiated with Adalimumab Plus Methotrexate Compared with Methotrexate Alone Following a Targeted Treatment Approach. <i>Rheumatology</i> , 2013, 52, i44-i55.	1.9	2
201	Patient Perspectives on Psoriasis Management: U.S. Results of the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. <i>Psoriasis Forum</i> , 2014, 20a, 124-131.	0.1	2
202	Addressing comorbidities in systemic inflammatory disorders. <i>Nature Reviews Rheumatology</i> , 2015, 11, 689-691.	8.0	2
203	GRAPPA 2019 Research Recipient Awards Report. <i>Journal of Rheumatology</i> , 2021, , jrheum.201682.	2.0	2
204	Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2016 MauiDerm Meeting based on presentations by. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2016, 9, S5-S29.	0.1	2
205	Association between TNFi anti-drug antibodies, smoking, and disease activity in patients with inflammatory arthritis: Results from a Norwegian cross-sectional observational study. <i>Rheumatology and Therapy</i> , 2022, 9, 1171-1179.	2.3	2
206	The treatment of psoriatic arthritis and inflammatory spondylitis. <i>Current Pain and Headache Reports</i> , 2008, 12, 412-417.	2.9	1
207	Guidelines in rheumatology: quo vadis?. <i>Nature Reviews Rheumatology</i> , 2009, 5, 423-424.	8.0	1
208	Do TNF inhibitors influence lymphoma development?. <i>Nature Reviews Rheumatology</i> , 2017, 13, 697-698.	8.0	1
209	258â€¦Secukinumab provides sustained improvements in the signs and symptoms in psoriatic arthritis: final 5-year efficacy and safety results from the FUTURE 1 Phase 3 trial. <i>Rheumatology</i> , 2019, 58, .	1.9	1
210	AB0742â€¦ACHIEVEMENT OF PASDAS LOW DISEASE ACTIVITY AND VERY LOW DISEASE ACTIVITY IN PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH CERTOLIZUMAB PEGOL OVER 4 YEARS AND THE OVERLAP WITH DAPSA AND MDA DISEASE ACTIVITY TARGETS. , 2019, , .		1
211	FRI0450â€¦PROBABILITY OF ACHIEVING LOW DISEASE ACTIVITY OR REMISSION IN SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS TREATED WITH APREMILAST. , 2019, , .		1
212	Anti-Citrullinated Protein Antibodies in Patients with Psoriatic Arthritis. <i>Rheumatology</i> , 2021, , .	1.9	1
213	Anticytokine Therapies. , 2013, , 957-977.e4.		1
214	Adalimumab for the treatment of rheumatoid arthritis. <i>Therapy: Open Access in Clinical Medicine</i> , 2005, 2, 13-21.	0.2	1
215	Elderly Onset Rheumatoid Arthritis. , 2011, , 145-150.		1
216	Trial design in psoriatic arthritis: what could be changed?. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S15-8.	0.8	1

#	ARTICLE	IF	CITATIONS
217	Clinically meaningful improvement in work productivity loss in active psoriatic arthritis: post-hoc analysis of SPIRIT-P1 and SPIRIT-P2 trials. Clinical and Experimental Rheumatology, 2020, 38, 1227-1230.	0.8	1
218	Clinical Controversies in Psoriatic Disease: The Use of IL-17i/IL-23i Versus TNFi as First-line Advanced Therapy in Psoriatic Arthritis. Journal of Rheumatology, 2022, , jrheum .211325.	2.0	1
219	Articular and Extra-Articular Benefits in ACR20 Non-responders at Week 104 Treated With Apremilast: Pooled Analysis of Three Randomized Controlled Trials. Rheumatology and Therapy, 2021, 8, 1677-1691.	2.3	1
220	Implications of radiographic joint damage in rheumatoid arthritis: Comment on the editorial by Weisman. Arthritis and Rheumatism, 2006, 54, 2035-2035.	6.7	0
221	Treatment options for psoriatic arthritis. Expert Opinion on Orphan Drugs, 2014, 2, 695-708.	0.8	0
222	How can the key findings from the GO-REVEAL study be translated to the clinic?. International Journal of Clinical Rheumatology, 2015, 10, 441-449.	0.3	0
223	195â€fSecukinumab Significantly Improves the Signs and Symptoms of Active Psoriatic Arthritis in Patients Previously Exposed to Anti-Tumour Necrosis Factor Therapy and Anti-Tumour Necrosis Factor-Naïve Patients: 52 Week Results from the Phase III Future 2 Trial. Rheumatology, 0, , .	1.9	0
224	069.â€fCONSTRUCT VALIDITY, RESPONSIVENESS AND MINIMALLY IMPORTANT DIFFERENCE OF THE ROUTINE ASSESSMENT OF PATIENT INDEX DATA 3 IN PSORIATIC ARTHRITIS. Rheumatology, 2017, 56, .	1.9	0
225	171â€fSecukinumab provides sustained PASDAS related low disease activity in psoriatic arthritis: two year results from the FUTURE 2 study. Rheumatology, 2018, 57, .	1.9	0
226	166â€fLong-term (156-week) improvements in dactylitis and enthesitis with apremilast in psoriatic arthritis subjects: analysis of a large, pooled PALACE 1-3 database. Rheumatology, 2018, 57, .	1.9	0
227	THU0044â€f...PRO- AND ANTI-INFLAMMATORY MEDIATORS OF SYSTEMIC INFLAMMATION AND ARTHRITIS IN THE ELDERLY. , 2019, , .		0
228	P261â€fContinuing versus withdrawing ixekizumab in patients with PsA who achieved sustained minimal disease activity: results from the SPIRIT-P3 study. Rheumatology, 2020, 59, .	1.9	0
229	Adalimumab in ankylosing spondylitis: an evidence-based review of its place in therapy. Core Evidence, 2008, 2, 295-305.	4.7	0
230	Autoimmune consequences of biologics. Journal of Allergy and Clinical Immunology, 2022, 149, 48-50.	2.9	0
231	2021 GRAPPA Meet the Experts Session: A Summary of Presentations.. Journal of Rheumatology, 2022, , .	2.0	0